NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing special-purpose nanomaterials for antiviral therapy, has filed its quarterly report on Form 10-Q for the fiscal quarter ended September 30, 2026, highlighting significant progress in advancing its broad-spectrum antiviral candidate NV-387 Oral Gummies into two Phase 2 clinical trials, according to a press release distributed via InvestorWire.
Enrollment began on September 23 for a Phase 2 trial evaluating NV-387 against Ebola Bundibugyo virus disease in the Democratic Republic of the Congo. A separate Phase 2 trial site opened the same day to evaluate the treatment for mpox. The company said it has independently funded the Ebola trial and established clinical testing infrastructure, including on-site molecular diagnostic capabilities, to support its research. These developments mark a critical step in testing NV-387 as a potential therapy for high-consequence viral diseases with limited treatment options.
NanoViricides also highlighted that the U.S. Food and Drug Administration granted Orphan Drug and Rare Pediatric Disease designations to NV-387 for measles treatment in April and May 2026, respectively. The company plans to pursue a Phase 2 measles trial and seek nondilutive funding, including potential U.S. government grants, to advance development. NV-387 remains investigational, with its effectiveness for these indications under clinical evaluation.
The advancement of NV-387 into Phase 2 trials for Ebola and mpox underscores the potential of the company's nanoviricide platform to address unmet medical needs in infectious diseases. For investors, the progress may signal a strengthening pipeline and could attract interest from government and non-profit funders focused on pandemic preparedness and biodefense. The independent funding of the Ebola trial demonstrates the company's commitment to moving its candidates forward despite the capital-intensive nature of drug development.
NanoViricides' lead drug candidate, NV-387, is being developed as a treatment for RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections and measles. The company's other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The company's business model is based on licensing technology from TheraCour Pharma, Inc. for specific application verticals of specific viruses.
For more details on the company's quarterly report and trial progress, the full press release can be viewed at https://ibn.fm/HChFn. Additional information about NanoViricides is available on its website at www.nanoviricides.com, and the latest news and updates relating to NNVC can be found in the company's newsroom at https://ibn.fm/NNVC.
The press release was distributed by InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which offers services including editorial syndication to 5,000+ outlets and corporate communications solutions. Full terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.

